证券代码：002675 证券简称：东诚药业 公告编号：2025-046 现将 225Ac-LNC1011 注射液相关情况公告如下： | 药物名称 | 注射液 225Ac-LNC1011 | | --- | --- | | 剂型 | 注射剂 | | 申请事项 | 临床试验 | | IND 号 | 175370 | | 审批结论 | 已完成对 注射液申请的安全性审核， FDA 225Ac-LNC1011 | | | 并认为可以继续进行拟议的前列腺癌临床研究。 | 一、药物的基本情况 二、药物的其他情况 烟台东诚药业集团股份有限公司 关于下属公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 2025 年 8 月 22 日，烟台东诚药业集团股份有限公司（以下简称"公司"） 下属公司 LNC PHARMA PTE. LTD. （以下简称"蓝纳成药业"）收到美国食品 药品监督管理局（以下简称"FDA"）核准签发的关于 225Ac-LNC1011 注射液的 药品临床试验批准通知书 (Study May Proceed Letter，以下简 ...

Group 1 - The actual controller of Yantai Dongcheng Pharmaceutical Group Co., Ltd., Mr. You Shouyi, has notified the company about the extension of the pledge of part of his shares [1] - As of August 21, 2025, Mr. You holds 103,305,678 shares of Dongcheng Pharmaceutical, with a total of 28,578,000 shares pledged, accounting for 27.66% of his total holdings [1] - The overall risk of share pledge is controllable, and there is currently no risk of forced liquidation [1][4] Group 2 - The actual controller and his concerted actors have a good credit status and possess the financial capability to repay, thus there is no risk of forced liquidation or transfer of control [4] - The company will continue to monitor the pledge situation and will disclose relevant information in a timely manner as required [4]

Group 1 - The core business of Dongcheng Pharmaceutical is entirely focused on the biopharmaceutical industry, with a revenue composition of 100% from this sector for the first half of 2025 [1] Group 2 - Dongcheng Pharmaceutical announced on August 21 that its actual controller, Mr. You Shouyi, has pledged part of his shares for extension. As of August 21, 2025, he holds approximately 103 million shares of Dongcheng Pharmaceutical, with a total of about 28.58 million shares pledged, accounting for 27.66% of his total holdings. The overall risk of share pledge is manageable, and there is currently no risk of forced liquidation [3]

Core Insights - The company reported a decline in revenue and net profit for the first half of 2025, with total revenue at 1.384 billion yuan, down 2.6% year-on-year, and net profit attributable to shareholders at 89 million yuan, down 20.7% [1] Financial Performance - Revenue for the nuclear medicine segment reached 503 million yuan, a year-on-year increase of 0.78%, with a gross margin of 67.27% [2] - The core product, 18F-FDG, generated revenue of 212 million yuan, reflecting an 8.72% increase year-on-year [2] - The raw material drug segment reported revenue of 611 million yuan, down 7.02%, primarily due to a decline in heparin sodium sales prices [2] Development Trends - The company has invested in 7 operational nuclear pharmacies focused on single-photon drugs and 22 on positron emission drugs, with 31 nuclear drug production centers currently in operation [2] - The company’s innovative nuclear drug pipeline is progressing, with the approval of sodium fluoride [18F] injection in May 2025 and ongoing clinical trials for several other products [3] Profit Forecast and Valuation - The company maintains its EPS forecast for 2025 and 2026 at 0.32 yuan and 0.40 yuan, respectively, with the current stock price corresponding to a P/E ratio of 55.1 times for 2025 and 43.9 times for 2026 [4] - The target price has been raised by 16.4% to 19.2 yuan, indicating an 8.8% upside potential from the current stock price [4]

证券代码：002675 证券简称：东诚药业 公告编号：2025-045 烟台东诚药业集团股份有限公司 关于实际控制人部分股权质押展期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 烟台东诚药业集团股份有限公司（以下简称"公司"或"本公司"）近日收 到公司实际控制人由守谊先生的通知，由守谊先生将其持有的本公司部分股权进 行质押展期，具体情况如下： 根据《通知》所述，截至2025年8月21日由守谊先生持有东诚药业股票 103,305,678股，累计质押28,578,000股，累计质押股份占所持股份总数的27.66%， 股权质押风险总体可控，目前不存在平仓风险。 注：质押股份均为高管锁定股。 上表中比例合计数与各数值直接相加之和在尾数上存在差异，是由于数字四舍五入原因造成的。 股东 名称 是否为控股 股东或第一 大股东及其 一致行动人 本次股份质 押展期数量 （股） 占其所 持股份 比例 占公 司总 股本 比例 是否为 限售股 是否为 补充质 押 质押起 始日 展期后质 押到期日 质权人 质押 用途 由守 谊 是 17,830,000 17.26% 2.16 ...

Core Insights - The release of the "2025 Shandong Private Enterprises Top 200" and other related rankings highlights the strength and vitality of the private economy in Yantai, with companies like Jereh Group, Xiwang Meat Products, and Dongcheng Pharmaceutical making notable appearances [1][2]. Group 1: Rankings Overview - The event announced four major lists: "2025 Shandong Private Enterprises Top 200," "2025 Shandong Private Enterprises Innovation Top 100," "2025 Shandong Private Enterprises Employment Top 100," and "2025 Shandong Private Enterprises Service Industry Top 100" [1]. - Jereh Group achieved recognition across three lists, showcasing its comprehensive strength, continuous innovation investment, and significant social contributions [1]. Group 2: Economic Environment - Yantai's continuous optimization of the business environment and strong support for market entities have led to significant achievements in industrial transformation and upgrading [2]. - The city has adopted a clear directive of "focusing on enterprises and strengthening them," providing multi-dimensional support to ensure the high-quality development of the private economy [2].

Group 1 - The company Dongcheng Pharmaceutical (002675) announced on August 18 that it will prioritize the outsourcing of its diagnostic product, Lanacheng, to Andico for production and sales [1] - Andico is also required to ensure the product demand for Lanacheng is met [1] - The cooperation model for therapeutic nuclear medicine products has not yet been determined [1]

Group 1: Financial Performance - The company achieved a revenue of 1.384 billion CNY, a year-on-year decrease of 2.60% [1] - The net profit attributable to shareholders was 89 million CNY, down 20.70% year-on-year [1] Group 2: Business Segment Performance - The nuclear medicine segment generated sales of 503 million CNY, a year-on-year increase of 0.78% [2] - Key product 18F-FDG sales reached 212 million CNY, up 8.72% due to increased sales volume [2] - Yunk injection sales were 116 million CNY, down 5.69% [2] - Iodine-125 sealed source sales were 70.89 million CNY, down 8.34% [2] - The raw material drug segment reported sales of 611 million CNY, a year-on-year decrease of 7.02% [2] - Heparin raw material sales were 440 million CNY, down 8.90% due to price declines [2] - Glucosamine sulfate sales were 165 million CNY, up 4.26% [2] - The formulation segment achieved sales of 182 million CNY, a year-on-year increase of 1.76% [2] Group 3: Research and Development - R&D expenses for the first half of 2025 totaled 121 million CNY, with 94.75 million CNY being expensed and 26.39 million CNY capitalized [10] - Ongoing clinical trials include: - 18F-SR peptide injection in Phase III [2] - 18F-alpha peptide injection in Phase III [2] - 18F-fibrin inhibitor and 177Lu-LNC1011 in Phase II [2] Group 4: Market and Regulatory Developments - 27 provinces and regions in China have issued medical service price lists, separating examination fees from drug costs, which is expected to boost FDG sales [4] - The company’s products, including Technetium-99m and Fluorine-18, are included in the 2025 medical insurance preliminary review directory, with negotiations expected to conclude in November [6] Group 5: Production Capacity and Infrastructure - The company operates 7 single-photon and 22 positron emission nuclear medicine production centers, with 31 centers in total, covering 93.5% of the domestic nuclear medicine demand [3] - The production center network is a core competitive advantage for the company [3] Group 6: Future Prospects and Strategic Directions - The company is exploring the combination of nuclear medicine with other treatment methods due to the complexity of tumors [15] - New targeted therapies are under development, including those targeting FAP and somatostatin receptors [16]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it indicates a positive trend in the pharmaceutical and biotechnology sector with a weekly increase of 3.08% [3][8]. Core Insights - The pharmaceutical and biotechnology sector outperformed the Wind All A index and the CSI 300 index during the week of August 11 to August 15, with notable gains in medical research outsourcing (7.77%), hospitals (5.59%), and medical consumables (4.47%) [3][8]. - The upcoming launch of the commercial insurance innovative drug directory is expected to activate the domestic high-end payment market for innovative drugs, with 121 drug names passing preliminary review [3][8]. - The World Conference on Lung Cancer (WCLC) will take place from September 6 to 9, showcasing significant research advancements in lung cancer, with domestic research playing an increasingly important role [3][8]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 3.08%, outperforming the Wind All A index (2.95%) and the CSI 300 index (2.37%) [3][8]. - Medical research outsourcing, hospitals, and medical consumables led the sector's gains, while offline pharmacies, blood products, and medical circulation experienced declines [3][8]. - Notable individual stock performances included Sino Medical (69.1%), Innovation Medical (51.5%), and Guangsheng Tang (40.7%) for gains, while *ST Suwu (-16.8%), ST Sansheng (-15.2%), and Nanhua Biological (-14.2%) faced significant losses [3][11]. Industry News and Key Company Announcements - The National Medical Insurance Administration announced the preliminary review of the 2025 National Basic Medical Insurance drug directory and the commercial insurance innovative drug directory [3][13]. - Novo Nordisk received accelerated FDA approval for its therapy Wegovy for treating non-alcoholic steatohepatitis (NASH) [3][13]. - Yunnan Baiyao approved a full acquisition of An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for 660 million RMB to enhance its traditional Chinese medicine business [3][15]. - Insmed's DPP1 inhibitor Brensocatib received FDA approval for treating non-cystic fibrosis bronchiectasis [3][14].

Core Viewpoint - The article highlights the recent adjustments made by well-known private equity fund managers in response to the disclosure of half-year reports by listed companies, indicating significant investment movements in the A-share market [1] Group 1: Investment Movements - A total of 12 private equity funds with over 10 billion yuan in assets have appeared among the top ten circulating shareholders of 18 A-share listed companies, with a combined holding value exceeding 18 billion yuan [1] - Gao Yi Asset's fund manager Feng Liu has increased his stake in Angel Yeast (600298), with the holding value rising to 1.23 billion yuan by the end of June [1] - Feng Liu has also slightly reduced his holdings in Hikvision (002415) and Dongcheng Pharmaceutical (002675) [1] Group 2: New Entrants - Ruijun Asset has newly entered the top ten circulating shareholders of Daozhi Technology (300409) [1] - Yinye Investment has also newly entered the top ten circulating shareholders of Haooubo [1] - Emerging institution Lexi Private Equity has invested over 500 million yuan to become the fifth largest circulating shareholder of Ninebot [1]